Our top pick for
Building a portfolio
Idera Pharmaceuticals, Inc is a biotechnology business based in the US. Idera Pharmaceuticals shares (IDRA) are listed on the NASDAQ and all prices are listed in US Dollars. Idera Pharmaceuticals employs 32 staff and has a market cap (total outstanding shares value) of USD$57 million.
|52-week range||USD$1.22 - USD$6.14|
|50-day moving average||USD$3.5049|
|200-day moving average||USD$3.7143|
|Wall St. target price||USD$1.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.661|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-16,707,000|
|Return on assets TTM||-51.02%|
|Return on equity TTM||-2280.6%|
|Market capitalisation||USD$57 million|
TTM: trailing 12 months
There are currently 2.2 million Idera Pharmaceuticals shares held short by investors – that's known as Idera Pharmaceuticals's "short interest". This figure is 169.4% up from 806,620 last month.
There are a few different ways that this level of interest in shorting Idera Pharmaceuticals shares can be evaluated.
Idera Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Idera Pharmaceuticals shares currently shorted divided by the average quantity of Idera Pharmaceuticals shares traded daily (recently around 778794.98207885). Idera Pharmaceuticals's SIR currently stands at 2.79. In other words for every 100,000 Idera Pharmaceuticals shares traded daily on the market, roughly 2790 shares are currently held short.
However Idera Pharmaceuticals's short interest can also be evaluated against the total number of Idera Pharmaceuticals shares, or, against the total number of tradable Idera Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Idera Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Idera Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0636% of the tradable shares (for every 100,000 tradable Idera Pharmaceuticals shares, roughly 64 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Idera Pharmaceuticals.
Find out more about how you can short Idera Pharmaceuticals stock.
We're not expecting Idera Pharmaceuticals to pay a dividend over the next 12 months.
Idera Pharmaceuticals's shares were split on a 1:8 basis on 29 July 2018. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Idera Pharmaceuticals shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Idera Pharmaceuticals shares which in turn could have impacted Idera Pharmaceuticals's share price.
Over the last 12 months, Idera Pharmaceuticals's shares have ranged in value from as little as $1.22 up to $6.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Idera Pharmaceuticals's is 1.8897. This would suggest that Idera Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.